Lv515
990 积分 2021-08-11 加入
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
12天前
已完结
The Role of MegaMolecule Antibody Structure in Internalization and Signaling
17天前
已完结
Advances in Systemic Treatment of Breast Cancer
19天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
24天前
已完结
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
1个月前
已完结
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
1个月前
已关闭
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials
2个月前
已完结
Hazard Ratio in Clinical Trials
2个月前
已关闭
Metronomics: towards personalized chemotherapy?
2个月前
已完结
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
